Serum A.Actinomycetemcomitans Antibodies and Periodontitis

Association Among Serum A.Actinomycetemcomitans Antibodies and Periodontitis

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04417322

Enrollment

221

Registered

2020-06-04

Start date

2016-04-15

Completion date

2020-03-25

Last updated

2020-06-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Periodontal Diseases

Brief summary

The aim of this study was to analyze the association between serum A.actinomycetemcomitans antibodies in patients with periodontitis. Furthermore, the objective was to determine if the periodontitis influenced serum IgG A.actinomycetemcomitans antibodies levels

Detailed description

53 patients with periodontitis and 48 healthy subjects (HS) were enrolled in the present study. Enrolled patients were examined and characterized for clinical and blood samples analysis and A.actinomycetemcomitans antibodies were expressed and evaluated enzyme-linked immunosorbent assay (ELISA) units (EU). The Spearman Correlation Test and Jonckheere-Terpstra Test were applied in order to assess the interdependence between serum IgG A.actinomycetemcomitans antibodies and clinical periodontal parameters.

Interventions

OTHERobservation of serum A.actinomycetemcomitans levels

Analysis of serum A.actinomycetemcomitans levels

Study design

Observational model

CASE_CONTROL

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Age

34 Years to 72 Years

Healthy volunteers

Yes

Inclusion criteria

* Presence of at least 15 teeth * CP with a minimum of 40% of sites with a clinical attachment level (CAL) ≥2mm and probing depth (PD) ≥4mm; * Presence of at least ≥2 mm of crestal alveolar bone loss verified on digital periapical radiographs * Presence of ≥40% sites with bleeding on probing (BOP)

Exclusion criteria

* Intake of contraceptives * Intake of immunosuppressive or anti-inflammatory drugs throughout the last three months prior to the study * Status of pregnancy or lactation * Previous history of excessive drinking * Allergy to local anaesthetic * Intake of drugs that may potentially determine gingival hyperplasia such as Hydantoin, Nifedipine, Cyclosporin A or similar drugs.

Design outcomes

Primary

Measure	Time frame	Description
Clinical Attachment Level	1-year	evaluation of changes in clinical attachment level

Countries

Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 25, 2026